Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]
Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]
Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee […]
By invitation only For more information, visit : www.keplercheuvreux.com Download management presentation
All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]
This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]
Hybrid Conference In-Person Location – New York City Click here for more information and to register
Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Click here to register To set up virtual meetings with […]
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
The management will comment the financial results and provide an update on the Company’s activities and perspectives through a video […]
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
More information coming soon
For more information, visit the MEET2WIN Convention website To meet with us during the Convention, please contact bd@onxeo.com
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
Watch the interview (in French)
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
Watch the e-poster “AsiDNA™ targets drug-tolerant persister cells responsible of resistance to PARP inhibitors”
For more information Download the presentation “AsiDNA™ and PARP inhibitors: Drug-driven synthetic lethality and beyond” Watch the video of […]
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
For more information and to register …
For more information, visit the Edison Open House Global Healthcare 2021 webpage Download the management presentation Access the interview […]
For more information, click here Download the management presentation
2020 Full-year report on the liquidity contract
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]